| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H11N3O2.ClH |
| Molecular Weight | 253.685 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCC1=C(NC(=O)N1)C(=O)C2=CC=NC=C2
InChI
InChIKey=SOIWUULWQIKDHV-UHFFFAOYSA-N
InChI=1S/C11H11N3O2.ClH/c1-2-8-9(14-11(16)13-8)10(15)7-3-5-12-6-4-7;/h3-6H,2H2,1H3,(H2,13,14,16);1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C11H11N3O2 |
| Molecular Weight | 217.2239 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Piroximone is a nonglycoside, noncatecholamine inotropic agent. In animal experiments, it has been shown to increase cardiac contractility by mechanisms unrelated to any known receptor, acting mainly by inhibition of type III phosphodiesterase. Piroximone also possesses direct vasodilatory properties in the arterial and venous vascular bed. Piroximone combines well-balanced vasodilator and inotropic properties which make it very useful for the management of congestive heart failure. Piroximone had been in phase II clinical trial for the treatment of heart failure. However, this research has been discontinued.
